Pharma China (www.pharmachinaonline.com) is the most influential English media and source of business intelligence covering the Chinese pharmaceutical sector. Pharma China caters for the growing needs of the international pharmaceutical industry for up-to-date and insightful information and intelligence on China’s burgeoning but increasingly complex healthcare marketplace, and is subscribed by most MNC pharma companies, leading CROs, investment banks, consulting firms active in China as well as relevant industry associations and government agencies.

Note: To view full text of free articles, you need to register as a basic member first and then log in. To view premium articles, you need to subscribe to Pharma China as a premium member. For more information or subscription, please contact info@pharmachinaonline.com. If you wish to unsubscribe from this e-Alert, please reply this e-mail with "Remove" in the subject line.
Editor´s Picks
CFDA's New Draft Policy Introduces the Chinese Version of Patent Linkage(6/15/2017 )  (Premium)
  This Lexology article by legal experts of Allen & Overy provides comments and translation of the Chinese proposed policy for pharmaceutical and medical device patent linkage.
APAC Is the Fastest Growing Market for CRO Industry(6/15/2017 )  (Premium)
  The CRO market in APAC, the fastest growing region in the world, has been increasing at a CAGR of 19.5%, according to this Biospectrum Asia Magazine interview with Ms Mary Pan, Vice President of Asia Pacific, ICON.
The Market
Snapshot of Drug Sales of Representative Hospitals in Shanghai 2016(6/12/2017 )  (Premium)
  The drug sales value at representative hospitals of Shanghai grew only 4.53% in 2016, reaching a total of CNY 3,901 million, according to the PDB database of China Pharmaceutical Industry Information Center (CPIIC).
Snapshot of Anti-hypertensive Drug Sales in Hospitals of Major Chinese Cities(6/12/2017 )  (Premium)
  Anti-hypertensive sales in urban hospitals of major Chinese cities is projected to be CNY 5,775 million in 2016, up 3.3% year on year, according to the PDB database of the China Pharmaceutical Industry Information Center (CPIIC).
Industry News
GSK, GIRD Enter Big Data Alliance for COPD Registry and Asthma Management(6/16/2017 )  (Premium)
  The strategic collaboration includes a prospective COPD registry study and "New Breath, Constant Care" China Asthma Patient Management Project. A health big data system will be developed through information sharing and covering different levels of healthcare organizations and reimbursement systems.
Croma-Pharma, Sihuan Pharma in Joint Venture Agreement in China(6/13/2017 )  (free)
  Croma-Pharma, one of only two European producers of Intradermal Fillers approved in China, announced the registration of Princess VOLUME and a Joint Venture with Sihuan Pharmaceutical Holdings Group Ltd.open the fastest growing market for aesthetic medicine "Made in Austria".
Snapshot: Sanofi's Chinese Urban Hospital Drug Sales Up 5.4% in 2016(6/13/2017 )  (Premium)
  Sanofi¡¯s sales in urban hospitals of major Chinese cities is projected to be nearly CNY 4,115 million in 2016, up only 5.4% year on year, according to the PDB database of the China Pharmaceutical Industry Information Center (CPIIC).
Wuxi Biologics Launches IPO in Hong Kong(6/12/2017 )  (free)
  On June 13, 2017, WuXi Biologics (Cayman) Inc. (2269.HK) was officially listed during a grand listing ceremony at the Main Board of The Stock Exchange of Hong Kong.
Japanese Pharma Positions for Growing Lifestyle Diseases in China and Rest of Asia(6/12/2017 )  (Premium)
  Japanese pharmaceutical companies are increasingly investing in China, India and other Asian markets outside their home country where lifestyle-related diseases are taking hold. The companies mostly plan to market drugs that have lost patent protection in Japan.
Windtree, Lee's Enter Into License Agreement for KL4 Surfactant Technology Platform in Asia(6/12/2017 )  (Premium)
  The agreement includes AEROSURF as well as the non-aerosol products SURFAXIN and SURFAXIN LS (an improved lyophilized formulation of SURFAXIN). Also, Windtree has granted Lee's an exclusive license to manufacture KL4 surfactant in China for use in non-aerosol surfactant products in the licensed territory.
CSL to Acquire Majority Stake in Plasma Product Producer Ruide Bio from Humanwell(6/12/2017 )  (Premium)
  Australian biotech giant CSL disclosed a deal on June 13 that will see it acquire an 80% stake in China's Wuhan Zhong Yuan Rui De Biologics (Ruide) for $352 million later this year.
Snapshot of Novartis's Flat Chinese Urban Hospital Drug Sales in 2016(6/12/2017 )  (Premium)
  Novartis's sales in urban hospitals of major Chinese cities is projected to be nearly CNY 4 billion in 2016, up only 1% year on year, according to the PDB database of the China Pharmaceutical Industry Information Center (CPIIC).
Regulatory News
CFDA Entrusts CPIA to Solicit Comments on Draft Provisions for Registration of Drug Products(6/16/2017 )  (Premium)
  Entrusted by the CFDA, the China Pharmaceutical Industry Association (CPIA) posted a notice at its website on June 15 to request comments from pharmaceutical enterprises for a new draft revision of the Provisions for Registration of Drug Products.
China Cracks CNY 400M Pharmaceutical Invoice Fraud Case(6/16/2017 )  (Premium)
  The Ministry of Public Security and the State General Administration of Taxation announced on June 15 that it has cracked a major invoice fraud/money laundering/tax evasion case involving more than 20 pharmaceutical companies and at least CNY 400 million.
General Health
Anhui Slashes BMI Payment Prices of Drug Products(6/14/2017 )  (Premium)
  Anhui Provincial Centralized Drug Purchase Tender Platform released a document, 2017 Anhui Provincial BMI Drug Reference Payment Prices. It contains 3,780 drug products and the 60% or 2,293 of them witness their prices slashed, according to a report of Saibailan.
Number of Private Hospitals Rising But Still Insignificant in China Healthcare(6/14/2017 )  (Premium)
  The total number of Chinese hospitals surged at the end of April 2017 to 29,478, driven by a rise of 1,786 private hospitals compare with one year ago to a total of 16,876. However, the number of public hospitals fell by 380 year on year to nearly 12,602.
NHFPC, SATCM Issue Joint Document to Crackdown on Healthcare Corruption(6/13/2017 )  (Premium)
  The NHFPC and the SATCM recently issued a new joint document, Opinions for Strengthening Industry Moral Building in the Health and Family Planning System, in an attempt to crackdown on corruption and boost professional morals in healthcare.
Product/R&D News
BeiGene Presents Phase 1 Data on BTK Inhibitor BGB-3111 Combined with Obinutuzumab(6/16/2017 )  (Premium)
  BeiGene presented on June 16 initial clinical data from an ongoing Phase 1 trial of the BTK inhibitor BGB-3111 combined with the anti-CD20 antibody obinutuzumab in patients with chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) and follicular lymphoma (FL) at the 14th International Conference on Malignant Lymphoma (14-ICML) in Lugano, Switzerland.
Six Agencies Issue Joint Special 13th FYP for Healthcare Industry Innovation(6/16/2017 )  (Premium)
  Six central government agencies, including the Ministry of Science and Technology (MOST), NDRC, MIIT, NHFPC, CFDA and the General Administration of Sport, issued a joint document, The Special 13th Five Year Plan for Healthcare Industry Science and Technology Innovation, on June 15.
China Investigates Claims of Academic Fraud Relating to Cancer Research(6/15/2017 )  (Premium)
  China is investigating claims of academic fraud involving mostly Chinese cancer researchers after more than 100 articles were withdrawn from a foreign medical journal.
Chi-Med Files Chinese NDA for Anticancer Fruquintinib(6/12/2017 )  (Premium)
  Hutchison China Meditech Ltd. (Chi-Med) said on June 12 that it has submitted a new drug application to the CFDA for fruquintinib, which is currently under consideration for use primarily as a treatment for advanced colorectal cancer.
People in the News
Recent Executive Moves(6/15/2017 )  (Premium)
  Latest Chinese pharma-related executive movements at companies including Pfizer China, Alcon China, Janssen China, DeltaHealth, Qilu Pharma, Zhongguancun Medical Engineering & Translation Center and Shanghai Fucare.
Recent CFDA Senior Official Moves(6/12/2017 )  (Premium)
  The CFDA announced numerous senior official appointments, retirements and removals on June 9.
© Wicon International Group¡¡Support by: www.heightow.com Home | Site map | Contact Us | Links